


## AMENDMENTS TO THE CLAIMS

1-46. (Canceled)


47. (Currently Amended) A method of ~~inhibiting the development of drug resistance in an HIV-infected mammal, treating a HIV-infected mammal who has developed resistance to HIV treatments,~~ the method comprising (i) determining whether the mammal has developed resistance to HIV treatments; (ii) administering to the HIV-infected mammal a ~~drug resistance-inhibiting~~ an effective amount of a compound of the formula:



(I),

or a pharmaceutically acceptable salt, a prodrug, or an ester thereof, or a pharmaceutically acceptable composition of said compound, said salt, said prodrug, or said ester thereof, wherein:

A is of the formula:



R<sup>1</sup> is H or an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkylalkyl, an aryl, an aralkyl, a heterocycloalkyl, a heterocycloalkylalkyl, a heteroaryl, or a heteroaralkyl, in which at least one hydrogen atom is optionally substituted with a substituent selected from the group consisting of OR<sup>7</sup>, SR<sup>7</sup>, CN, NO<sub>2</sub>, N<sub>3</sub>, and a halogen, wherein R<sup>7</sup> is H, an unsubstituted alkyl, an unsubstituted alkenyl, or an unsubstituted alkynyl;

Y and Z are the same or different and each is selected from the group consisting of CH<sub>2</sub>, O, S, SO, SO<sub>2</sub>, NR<sup>8</sup>, R<sup>8</sup>C(O)N, R<sup>8</sup>C(S)N, R<sup>8</sup>OC(O)N, R<sup>8</sup>OC(S)N, R<sup>8</sup>SC(O)N,

$R^8R^9NC(O)N$ , and  $R^8R^9NC(S)N$ , wherein  $R^8$  and  $R^9$  are each selected from the group consisting of H, an unsubstituted alkyl, an unsubstituted alkenyl, and an unsubstituted alkynyl;

$n$  is an integer from 1 to 5;

$X$  is a covalent bond,  $CHR^{10}$ ,  $CHR^{10}CH_2$ ,  $CH_2CHR^{10}$ , O,  $NR^{10}$ , or S, wherein  $R^{10}$  is H, an unsubstituted alkyl, an unsubstituted alkenyl, or an unsubstituted alkynyl;

$Q$  is  $C(O)$ ,  $C(S)$ , or  $SO_2$ ;

$R^2$  is H, a  $C_1$ - $C_6$  alkyl, a  $C_2$ - $C_6$  alkenyl, or a  $C_2$ - $C_6$  alkynyl;

$m$  is an integer from 0 to 6;

$R^3$  is a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl in which at least one hydrogen atom is optionally substituted with a substituent selected from the group consisting of alkyl,  $(CH_2)_pR^{11}$ ,  $OR^{12}$ ,  $SR^{12}$ , CN,  $N_3$ ,  $NO_2$ ,  $NR^{12}R^{13}$ ,  $C(O)R^{12}$ ,  $C(S)R^{12}$ ,  $CO_2R^{12}$ ,  $C(O)SR^{12}$ ,  $C(O)NR^{12}R^{13}$ ,  $C(S)NR^{12}R^{13}$ ,  $NR^{12}C(O)R^{13}$ ,  $NR^{12}C(S)R^{13}$ ,  $NR^{12}CO_2R^{13}$ ,  $NR^{12}C(O)SR^{13}$ , and a halogen, wherein:

$p$  is an integer from 0 to 5;

$R^{11}$  is a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl in which at least one hydrogen atom is optionally substituted with a substituent selected from the group consisting of a halogen, OH,  $OCH_3$ ,  $NH_2$ ,  $NO_2$ , SH, and CN; and

$R^{12}$  and  $R^{13}$  are the same or different and each is selected from the group consisting of H, an unsubstituted alkyl, an unsubstituted alkenyl, and an unsubstituted alkynyl;

$R^4$  is OH, =O (keto) or  $NH_2$ , wherein, when  $R^4$  is OH, it is optionally in the form of a pharmaceutically acceptable ester or prodrug, and when  $R^4$  is  $NH_2$ , it is optionally an amide, a hydroxylamino, a carbamate, a urea, an alkylamino, a dialkylamino, a protic salt thereof, or a tetraalkylammonium salt thereof;

$R^5$  is H, a  $C_1$ - $C_6$  alkyl radical, a  $C_2$ - $C_6$  alkenyl radical, or  $(CH_2)_qR^{14}$ , wherein  $q$  is an integer from 0 to 5, and  $R^{14}$  is a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl radical in which at least one hydrogen atom is optionally substituted with a substituent selected from the group consisting of a halogen, OH,  $OCH_3$ ,  $NH_2$ ,  $NO_2$ , SH, and CN;

$W$  is  $C(O)$ ,  $C(S)$ , or  $SO_2$ ; and

$R^6$  is a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl radical in which at least one hydrogen atom is optionally substituted with a substituent selected from the group consisting of a halogen,  $OR^{15}$ ,  $SR^{15}$ ,  $S(O)R^{15}$ ,  $SO_2R^{15}$ ,  $SO_2NR^{15}R^{16}$ ,  $SO_2N(OH)R^{15}$ , CN,  $CR^{15}=NR^{16}$ ,

$CR^{15}=N(OR^{16})$ ,  $N_3$ ,  $NO_2$ ,  $NR^{15}R^{16}$ ,  $N(OH)R^{15}$ ,  $C(O)R^{15}$ ,  $C(S)R^{15}$ ,  $CO_2R^{15}$ ,  $C(O)SR^{15}$ ,  
 $C(O)NR^{15}R^{16}$ ,  $C(S)NR^{15}R^{16}$ ,  $C(O)N(OH)R^{15}$ ,  $C(S)N(OH)R^{15}$ ,  $NR^{15}C(O)R^{16}$ ,  $NR^{15}C(S)R^{16}$ ,  
 $N(OH)C(O)R^{15}$ ,  $N(OH)C(S)R^{15}$ ,  $NR^{15}CO_2R^{16}$ ,  $N(OH)CO_2R^{15}$ ,  $NR^{15}C(O)SR^{16}$ ,  
 $NR^{15}C(O)NR^{16}R^{17}$ ,  $NR^{15}C(S)NR^{16}R^{17}$ ,  $N(OH)C(O)NR^{15}R^{16}$ ,  $N(OH)C(S)NR^{15}R^{16}$ ,  
 $NR^{15}C(O)N(OH)R^{16}$ ,  $NR^{15}C(S)N(OH)R^{16}$ ,  $NR^{15}SO_2R^{16}$ ,  $NHSO_2NR^{15}R^{16}$ ,  $NR^{15}SO_2NHR^{16}$ ,  
 $P(O)(OR^{15})(OR^{16})$ , an alkyl, an alkoxy, an alkylthio, an alkylamino, a cycloalkyl, a  
cycloalkylalkyl, a heterocycloalkyl, a heterocycloalkylalkyl, an aryl, an aryloxy, an  
arylamino, an arylthio, an aralkyl, an aryloxyalkyl, an arylaminoalkyl, an aralkoxy, an  
(aryloxy)alkoxy, an (arylamino)alkoxy, an (arylthio)alkoxy, an aralkylamino, an  
(aryloxy)alkylamino, an (arylamino)alkylamino, an (arylthio)alkylamino, an aralkylthio, an  
(aryloxy)alkylthio, an (arylamino)alkylthio, an (arylthio)alkylthio, a heteroaryl, a  
heteroaryloxy, a heteroarylamino, a heteroarylthio, a heteroaralkyl, a heteroaralkoxy, a  
heteroaralkylamino, and a heteroaralkylthio,

wherein  $R^{15}$ ,  $R^{16}$ , and  $R^{17}$  are the same or different and each is H, an  
unsubstituted alkyl, or an unsubstituted alkenyl,

wherein, when at least one hydrogen atom of  $R^6$  is substituted with a  
substituent other than a halogen,  $OR^{15}$ ,  $SR^{15}$ ,  $CN$ ,  $N_3$ ,  $NO_2$ ,  $NR^{15}R^{16}$ ,  $C(O)R^{15}$ ,  $C(S)R^{15}$ ,  
 $CO_2R^{15}$ ,  $C(O)SR^{15}$ ,  $C(O)NR^{15}R^{16}$ ,  $C(S)NR^{15}R^{16}$ ,  $NR^{15}C(O)R^{16}$ ,  $NR^{15}C(S)R^{16}$ ,  $NR^{15}CO_2R^{16}$ ,  
 $NR^{15}C(O)SR^{16}$ ,  $NR^{15}C(O)NR^{16}R^{17}$ , or  $NR^{15}C(S)NR^{16}R^{17}$ , at least one hydrogen atom on said  
substituent is optionally substituted with a halogen,  $OR^{15}$ ,  $SR^{15}$ ,  $CN$ ,  $N_3$ ,  $NO_2$ ,  $NR^{15}R^{16}$ ,  
 $C(O)R^{15}$ ,  $C(S)R^{15}$ ,  $CO_2R^{15}$ ,  $C(O)SR^{15}$ ,  $C(O)NR^{15}R^{16}$ ,  $C(S)NR^{15}R^{16}$ ,  $NR^{15}C(O)R^{15}$ ,  
 $NR^{15}C(S)R^{16}$ ,  $NR^{15}CO_2R^{16}$ ,  $NR^{15}C(O)SR^{16}$ ,  $NR^{15}C(O)NR^{16}R^{17}$ , or  $NR^{15}C(S)NR^{16}R^{17}$ ; and

~~wherein a mutant virus that is capable of evolving from the HIV virus infecting said  
mammal has lower fitness, relative to said HIV virus infecting said mammal, in the presence  
of said compound.~~

(iii) administering at least one antiviral agent selected from the group consisting of  
ritonavir, indinavir, amprenavir and saquinavir;

whereby the HIV-infected mammal is treated.

48. (Canceled)

49. (Previously Presented) The method of claim 47, wherein:

when  $R^1$  is an alkyl, it is a  $C_1$ - $C_6$  alkyl;

when  $R^1$  is an alkenyl it is a  $C_2$ - $C_6$  alkenyl;

when  $R^1$  is a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl,  $R^1$  is a 4-7 membered ring;

when  $R^7$ ,  $R^8$  or  $R^9$  is an unsubstituted alkyl, it is a  $C_1$ - $C_6$  unsubstituted alkyl;

when  $R^7$ ,  $R^8$  or  $R^9$  is an unsubstituted alkenyl, it is a  $C_2$ - $C_6$  unsubstituted alkenyl;

$R^3$  is a 4-7 membered ring;

$R^{11}$  is a 4-7 membered ring;

when  $R^{12}$  or  $R^{13}$  is an unsubstituted alkyl, it is a  $C_1$ - $C_6$  unsubstituted alkyl;

when  $R^{12}$  or  $R^{13}$  is an unsubstituted alkenyl, it is a  $C_2$ - $C_6$  unsubstituted alkyl;

when  $R^{14}$  is a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl,  $R^{14}$  is a 4-7 membered ring;

when  $R^6$  is a cycloalkyl, a heterocycloalkyl, aryl, or a heteroaryl,  $R^6$  is a 4-7 membered ring;


when  $R^6$  is substituted with a substituent that is an alkyl, an alkylthio, or an alkylamino, the substituent comprises from one to six carbon atoms; and

when  $R^6$  is substituted with a substituent that is a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl, the substituent is a 4-7 membered ring;


or a pharmaceutically acceptable salt, a prodrug, or an ester thereof.

50. (Previously Presented) The method of claim 47, wherein Q is C(O),  $R^2$  is H, and W is  $SO_2$ , or a pharmaceutically acceptable salt, a prodrug, or an ester thereof.

51. (Previously Presented) The method of claim 47, wherein the compound is represented by the formula:




(IA) or




(IB).

52. (Previously Presented) The method of claim 51, wherein the compound is represented by the formula:



(IC)


or



(ID),


wherein  $Ar$  is a phenyl which is optionally substituted with a substituent selected from the group consisting of methyl, amino, hydroxy, methoxy, methylthio, hydroxymethyl, aminomethyl, and methoxymethyl.

53. (Previously Presented) The method of claim 52, wherein the compound is represented by the formula:



(IE)

or



(IF).

54. (Previously Presented) The method of claim 52, wherein X is oxygen.
55. (Previously Presented) The method of claim 52, wherein R<sup>5</sup> is isobutyl.
56. (Previously Presented) The method of claim 52, wherein Ar is a phenyl substituted at the para-position.
57. (Previously Presented) The method of claim 52, wherein Ar is a phenyl substituted at the meta-position.

58. (Previously Presented) The method of claim 52, wherein Ar is a phenyl substituted at the ortho-position.

59. (Previously Presented) The method of claim 52, wherein Ar is selected from the group consisting of para-aminophenyl, para-toluy, para-methoxyphenyl, meta-methoxyphenyl, and meta-hydroxymethylphenyl.


60. (Previously Presented) The method of claim 47, wherein the HIV-infected mammal is infected with a wild-type HIV.

61. (Previously Presented) The method of claim 47, wherein the HIV-infected mammal is infected by a mutant HIV with least one protease mutation.

62. (Previously Presented) The method of claim 47, wherein the HIV-infected mammal is infected by a mutant HIV having at least one reverse transcriptase mutation.

63-78. (Canceled)

79. (Previously Presented) The method of claim 47, wherein A is of the formula:



80. (Canceled)

81. (Currently Amended) The method of claim 47, wherein the at least one antiviral agent is ritonavir. ~~which comprises further administration of at least one antiviral agent selected from the group consisting of ritonavir, indinavir, amprenavir and saquinavir.~~